Download PDF
Anästhesiol Intensivmed Notfallmed Schmerzther 2003; 38(6): 403-437
DOI: 10.1055/s-2003-39360
Fort- und Weiterbildung
© Georg Thieme Verlag Stuttgart · New York

Tumorschmerztherapie

Tumor Pain TreatmentH.  Ohnesorge1 , D.  Siebrecht1 , M.  Gleim1
  • 1Klinik für Anästhesiologie und operative Intensivmedizin, Universitätsklinikum Kiel
Further Information

Publication History

Publication Date:
21 May 2003 (online)

Also available at
    Permissions and Reprints

Weiterbildungsziele

In diesem Beitrag sollen folgende Weiterbildungsziele vermittelt werden:

  • Prävalenz von Tumorschmerzen

  • Ätiologie und Klassifikation von Tumorschmerzen

  • Ziele der Tumorschmerztherapie

  • Grundlegende Aspekte der Tumorschmerztherapie

  • Empfehlungen der Weltgesundheitsorganisation

  • Nicht Opioid-Analgetika

    • Acetylsalicylsäure (ASS)

    • NSAIDs

    • Coxibe

    • Paracetamol

    • Pyrazinolon-Derivate

    • Flupirtin

  • Opioide

    • Opioide der Stufe II des WHO Stufen-Schemas

    • Opioide der Stufe III des WHO Stufen-Schemas

  • Co-Analgetika

    • Trizyklische Antidepressiva

    • Antikonvulsiva

    • Bisphosphonate

    • Kortikosteroide

    • Cannabinoide

  • Adjuvante Medikation

    • Laxantien

    • Antiemetika

    • Ulkus-Prophylaxe

  • Praktische Empfehlung zur medikamentösen Behandlung von Tumorschmerzen

  • Interventionelle Schmerztherapie

    • Rückenmarknahe Analgesieverfahren

    • Neuroablative Verfahren

Literatur

  • 1 Deutsche Krebsgesellschaft .Kurzgefasste Interdisziplinäre Leitlinien 2002. 2002 3
    Google Scholar
  • 2 Ensink F BM, Beck D, Bautz M T, Hanekop G G. Tumorschmerztherapie Teil 1: Prävalenz und Klassifikation von Tumorschmerzen.  Niedersächsisches Ärzteblatt. 1999;  72 1-4
    PubMedGoogle Scholar
  • 3 Cleeland C S, Gonin R, Hatfield A K, Edmonson J H, Blum R H, Stewart J A, Pandya K J. Pain and its treatment in outpatients with metastatic cancer.  N Engl J Med. 1994;  330 (9) 592-596
    CrossrefPubMedGoogle Scholar
  • 4 Bonica J J. Cancer pain,. in: Bonica J.J The management of pain. Lea & Fiebiger: Philadelphia/London 1990: 400-460
    Google Scholar
  • 5 Caraceni A, Portenoy R K. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain.  Pain. 1999;  82 (3) 263-74
    CrossrefPubMedGoogle Scholar
  • 6 Heidemann E. Malignome und Prävalenz von Schmerz,. in: H. Beck, et al Schmerztherapie. Thieme: Stuttgart/New York 2002: 515-517
    Google Scholar
  • 7 Portenoy R K. Cancer pain. Epidemiology and syndromes.  Cancer. 1989;  63 (11 Suppl) 2298-2307
    PubMedGoogle Scholar
  • 8 Twycross R. Cancer pain classification.  Acta Anaesthesiol Scand. 1997;  41 (1 Pt 2) 141-145
    PubMedGoogle Scholar
  • 9 Deutsche Gesellschaft für Anästhesie und Intensivmedizin . Grenzen der intensivmedizinischen Behandlungspflicht.  Anästhesie & Intensivmedizin. 1999;  40 (2) 99ff
    PubMedGoogle Scholar
  • 10 Gonzales G R, Elliott K J, Portenoy R K, Foley K M. The impact of a comprehensive evaluation in the management of cancer pain.  Pain. 1991;  47 (2) 141-144
    CrossrefPubMedGoogle Scholar
  • 11 Schug S A, Zech D, Dorr U. Cancer pain management according to WHO analgesic guidelines.  J Pain Symptom Manage. 1990;  5 (1) 27-32
    CrossrefPubMedGoogle Scholar
  • 12 World-Health-Organisation .Cancer pain relief. Genf: World Health Organisation 1986
    Google Scholar
  • 13 Zech D F, Grond S, Lynch J, Hertel D, Lehmann K A. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study.  Pain. 1995;  63 (1) 65-76
    CrossrefPubMedGoogle Scholar
  • 14 Ventafridda V, Tamburini M, Caraceni A, de Conno F, Naldi F. A validation study of the WHO method for cancer pain relief.  Cancer. 1987;  59 (4) 850-856
    CrossrefPubMedGoogle Scholar
  • 15 Jadad A R, Browman G P. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation.  Jama. 1995;  274 (23) 1870-1873
    CrossrefPubMedGoogle Scholar
  • 16 Mukherjee D, Nissen S E, Topol E J. Risk of cardiovascular events associated with selective COX-2 inhibitors.  Jama. 2001;  286 (8) 954-959
    CrossrefPubMedGoogle Scholar
  • 17 Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz M B, Hawkey C J, Hochberg M C, Kvien T K, Schnitzer T J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.  N Engl J Med. 2000;  343 (21) 1520-1528, 2 p following 1528
    CrossrefPubMedGoogle Scholar
  • 18 Silverstein F E, Faich G, Goldstein J L, Simon L S, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal N M, Stenson W F, Burr A M, Zhao W W, Kent J D, Lefkowith J B, Verburg K M, Geis G S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti- inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.  Jama. 2000;  284 (10) 1247-1255
    CrossrefPubMedGoogle Scholar
  • 19 Henry D, Lim L L-Y, Rodriguez L AG, Gutthann S P, Carson J L, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, Hill S, Fries J T. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis.  BMJ. 1996;  312 (7046) 1563-1566
    CrossrefPubMedGoogle Scholar
  • 20 Juni P, Rutjes A W, Dieppe P A. Are selective COX-2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?.  BMJ. 2002;  324 (7349) 1287-1288
    CrossrefPubMedGoogle Scholar
  • 21 Blanke C D. Celecoxib with chemotherapy in colorectal cancer.  Oncology (Huntingt). 2002;  16 (4 Suppl 3) 17-21
    PubMedGoogle Scholar
  • 22 Edwards J G, Faux S P, Plummer S M, Abrams K R, Walker R A, Waller D A, O'Byrne K J. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.  Clin Cancer Res. 2002;  8 (6) 1857-1862
    PubMedGoogle Scholar
  • 23 Ventafridda V, de Conno F, Panerai A E, Maresca V, Monza G C, Ripamonti C. Non-steroidal anti-inflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs.  J Int Med Res. 1990;  18 (1) 21-29
    PubMedGoogle Scholar
  • 24 Bjorkman R, Hallman K M, Hedner J, Hedner T, Henning M. Acetaminophen blocks spinal hyperalgesia induced by NMDA and substance P.  Pain. 1994;  57 (3) 259-264
    CrossrefPubMedGoogle Scholar
  • 25 Kornhuber J, Maler M, Wiltfang J, Bleich S, Degner D, Ruther E. [Neuronal potassium channel opening with flupirtine].  Fortschr Neurol Psychiatr. 1999;  67 (10) 466-475
    PubMedGoogle Scholar
  • 26 Schwarz M, Schmitt T, Pergande G, Block F. N-methyl-D-aspartate and alpha 2-adrenergic mechanisms are involved in the depressant action of flupirtine on spinal reflexes in rats.  Eur J Pharmacol. 1995;  276 (3) 247-255
    CrossrefPubMedGoogle Scholar
  • 27 Friedel H A, Fitton A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states.  Drugs. 1993;  45 (4) 548-569
    CrossrefPubMedGoogle Scholar
  • 28 arznei-telegramm . Leberschäden durch Analgetikum. Flupirtin.  2000;  31 (3) 30
    Google Scholar
  • 29 Eichelbaum M, Evert B. Influence of pharmacogenetics on drug disposition and response.  Clin Exp Pharmacol Physiol. 1996;  23 (10-11) 983-985
    PubMedGoogle Scholar
  • 30 Lewis K S, Han N H. Tramadol: a new centrally acting analgesic.  Am J Health Syst Pharm. 1997;  54 (6) 643-652
    PubMedGoogle Scholar
  • 31 Wehrmann T, Rausch D, Seiler K U, Brennscheidt U, Caspary W F. Tilidine does not affect human sphincter of Oddi motility - a randomized, controlled study.  Aliment Pharmacol Ther. 1997;  11 (5) 987-992
    CrossrefPubMedGoogle Scholar
  • 32 Hanks G W, Conno F, Cherny N, Hanna M, Kalso E, McQuay H J, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Casas J R, Sawe J, Twycross R G, Ventafridda V. Morphine and alternative opioids in cancer pain: the EAPC recommendations.  Br J Cancer. 2001;  84 (5) 587-593
    CrossrefPubMedGoogle Scholar
  • 33 Heiskanen T, Kalso E. Controlled-release oxycodone and morphine in cancer related pain.  Pain. 1997;  73 (1) 37-45
    CrossrefPubMedGoogle Scholar
  • 34 Hagen N A, Babul N. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain.  Cancer. 1997;  79 (7) 1428-1437
    CrossrefPubMedGoogle Scholar
  • 35 Grond S, Radbruch L, Lehmann K A. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl.  Clin Pharmacokinet. 2000;  38 (1) 59-89
    CrossrefPubMedGoogle Scholar
  • 36 Donner B, Zenz M, Strumpf M, Raber M. Long-term treatment of cancer pain with transdermal fentanyl.  J Pain Symptom Manage. 1998;  15 (3) 168-175
    CrossrefPubMedGoogle Scholar
  • 37 Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.  Drugs. 1997;  53 (1) 109-138
    PubMedGoogle Scholar
  • 38 Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group.  J Pain Symptom Manage. 1997;  13 (5) 254-261
    CrossrefPubMedGoogle Scholar
  • 39 Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain.  Pain. 1996;  64 (3) 527-534
    CrossrefPubMedGoogle Scholar
  • 40 Arzneimittelkommision-der-deutschen-Ärzteschaft .Therapieempfehlungen Tumorschmerz. 2000 2
    Google Scholar
  • 41 Portenoy R K, Payne R, Coluzzi P, Raschko J W, Lyss A, Busch M A, Frigerio V, Ingham J, Loseth D B, Nordbrock E, Rhiner M. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.  Pain. 1999;  79 (2-3) 303-312
    CrossrefPubMedGoogle Scholar
  • 42 Coluzzi P H, Schwartzberg L, Conroy J D, Charapata S, Gay M, Busch M A, Chavez J, Ashley J, Lebo D, McCracken M, Portenoy R K. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).  Pain. 2001;  91 1-2. 123-130
    CrossrefPubMedGoogle Scholar
  • 43 Plummer J L, Gourlay G K, Cherry D A, Cousins M J. Estimation of methadone clearance: application in the management of cancer pain.  Pain. 1988;  33 (3) 313-322
    CrossrefPubMedGoogle Scholar
  • 44 Gorman A L, Elliott K J, Inturrisi C E. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord.  Neurosci Lett. 1997;  223 (1) 5-8
    CrossrefPubMedGoogle Scholar
  • 45 Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P, Gebbia V, Ripamonti C. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study.  J Clin Oncol. 2001;  19 (11) 2898-2904
    PubMedGoogle Scholar
  • 46 Bulka A, Plesan A, Xu X J, Wiesenfeld-Hallin Z. Reduced tolerance to the anti-hyperalgesic effect of methadone in comparison to morphine in a rat model of mononeuropathy.  Pain. 2002;  95 (1-2) 103-109
    CrossrefPubMedGoogle Scholar
  • 47 Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, de Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?.  J Clin Oncol. 1998;  16 (10) 3216-3221
    PubMedGoogle Scholar
  • 48 Rowbotham M C, Reisner-Keller L A, Fields H L. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia.  Neurology. 1991;  41 (7) 1024-1028
    CrossrefPubMedGoogle Scholar
  • 49 Dellemijn P L, Vanneste J A. Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain.  Lancet. 1997;  349 (9054) 753-758
    CrossrefPubMedGoogle Scholar
  • 50 McQuay H J, Tramer M, Nye B A, Carroll D, Wiffen P J, Moore R A. A systematic review of antidepressants in neuropathic pain.  Pain. 1996;  68 (2-3) 217-227
    CrossrefPubMedGoogle Scholar
  • 51 Kingery W S. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes.  Pain. 1997;  73 (2) 123-139
    CrossrefPubMedGoogle Scholar
  • 52 Kalso E, Tasmuth T, Neuvonen P J. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer.  Pain. 1996;  64 (2) 293-302
    CrossrefPubMedGoogle Scholar
  • 53 Baron R. [Neuropathic pain. The long path from mechanisms to mechanism-based treatment].  Anaesthesist. 2000;  49 (5) 373-386
    CrossrefPubMedGoogle Scholar
  • 54 Ventafridda V, Bianchi M, Ripamonti C, Sacerdote P, de Conno F, Zecca E, Panerai A E. Studies on the effects of antidepressant drugs on the antinociceptive action of morphine and on plasma morphine in rat and man.  Pain. 1990;  43 (2) 155-162
    CrossrefPubMedGoogle Scholar
  • 55 Max M B, Lynch S A, Muir J, Shoaf S E, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.  N Engl J Med. 1992;  326 (19) 1250-1256
    CrossrefPubMedGoogle Scholar
  • 56 Feuerstein T J. Antidepressiva zur Therapie chronischer Schmerzen. Metaanalyse.  Der Schmerz. 1997;  11 213-226
    CrossrefPubMedGoogle Scholar
  • 57 McQuay H J, Moore R A. Antidepressants and chronic pain.  Bmj. 1997;  314 (7083) 763-764
    PubMedGoogle Scholar
  • 58 McQuay H, Carroll D, Jadad A R, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review.  Bmj. 1995;  311 (7012) 1047-1052
    PubMedGoogle Scholar
  • 59 McNamara J O. Drugs effective in the Therapy of Epilepsies, in Goodman & Gillman's. J.G. Hardman and L.E. Limbird, Editors The pharmacological Basis of Therapeutics. Mc Graw-Hill: New York 2001: 521-547
    Google Scholar
  • 60 Dirks J, Fredensborg B B, Christensen D, Fomsgaard J S, Flyger H, Dahl J B. A randomized study of the effects of single-dose gabapentin versus placebo on postoperative pain and morphine consumption after mastectomy.  Anesthesiology. 2002;  97 (3) 560-564
    CrossrefPubMedGoogle Scholar
  • 61 Caraceni A, Zecca E, Martini C, de Conno F. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain.  J Pain Symptom Manage. 1999;  17 (6) 441-445
    CrossrefPubMedGoogle Scholar
  • 62 Clezardin P, Gligorov J, Delmas P. Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis.  Joint Bone Spine. 2000;  67 (1) 22-29
    PubMedGoogle Scholar
  • 63 Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials.  Pain. 1998;  78 (3) 157-169
    CrossrefPubMedGoogle Scholar
  • 64 Pavlakis N, Stockler M. Bisphosphonates for breast cancer.  Cochrane Database Syst Rev. 2002;  1 CD003474
    PubMedGoogle Scholar
  • 65 Zimmer A, Zimmer A M, Hohmann A G, Herkenham M, Bonner T I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice.  Proc Natl Acad Sci USA. 1999;  96 (10) 5780-5785
    CrossrefPubMedGoogle Scholar
  • 66 Zygmunt P M, Andersson D A, Hogestatt E D. Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism.  J Neurosci. 2002;  22 (11) 4720-4727
    PubMedGoogle Scholar
  • 67 Campbell F A, Tramer M R, Carroll D, Reynolds D J, Moore R A, McQuay H J. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review.  Bmj. 2001;  323 (7303) 13-16
    CrossrefPubMedGoogle Scholar
  • 68 Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction.  Am J Surg. 2001;  182 (5A Suppl) 11S-18S
    CrossrefPubMedGoogle Scholar
  • 69 Yeomans N D, Tulassay Z, Juhasz L, Racz I, Howard J M, van Rensburg C J, Swannell A J, Hawkey C J. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.  N Engl J Med. 1998;  338 (11) 719-726
    CrossrefPubMedGoogle Scholar
  • 70 Eisenberg E, Berkey C S, Carr D B, Mosteller F, Chalmers T C. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis.  J Clin Oncol. 1994;  12 (12) 2756-2765
    PubMedGoogle Scholar
  • 71 Mercadante S, Villari P, Ferrera P, Casuccio A, Fulfaro F. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion.  Cancer. 2002;  95 (1) 203-208
    CrossrefPubMedGoogle Scholar
  • 72 Eisenberg E, Carr D B, Chalmers T C. Neurolytic celiac plexus block for treatment of cancer pain: a meta- analysis.  Anesth Analg. 1995;  80 (2) 290-295
    CrossrefPubMedGoogle Scholar
  • 73 Polati E, Finco G, Gottin L, Bassi C, Pederzoli P, Ischia S. Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer.  Br J Surg. 1998;  85 (2) 199-201
    CrossrefPubMedGoogle Scholar
  • 74 Kawamata M, Ishitani K, Ishikawa K, Sasaki H, Ota K, Omote K, Namiki A. Comparison between celiac plexus block and morphine treatment on quality of life in patients with pancreatic cancer pain.  Pain. 1996;  64 (3) 597-602
    CrossrefPubMedGoogle Scholar
  • 75 Gutstein H B, Akil H. Opioid Analgesics. J.G. Hardman and L.E. Limbird, Editors Goodman & Gillman's The pharmacological Basis of Therapeutics. Mc Graw-Hill: New York 2001: 569-620
    Google Scholar

Dr. Henning Ohnesorge

Klinik für Anästhesiologie und operative Intensivmedizin, Universitätsklinikum Kiel

Schwanenweg 21

24105 Kiel

Email: ohnesorge@anaesthesie.uni-kiel.de

      >